According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, Jefferies Group restated a hold rating on shares of Enzymotec in a report on Thursday, August 4th.
Enzymotec (NASDAQ:ENZY) remained flat at $7.10 on Tuesday. The firm has a market capitalization of $161.30 million, a price-to-earnings ratio of 37.37 and a beta of 1.27. Enzymotec has a 1-year low of $6.60 and a 1-year high of $10.32. The firm’s 50 day moving average price is $7.28 and its 200 day moving average price is $8.12.
Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings results on Tuesday, August 9th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by $0.04. Enzymotec had a return on equity of 3.12% and a net margin of 8.37%. The business earned $15 million during the quarter, compared to the consensus estimate of $14.90 million. During the same quarter last year, the firm posted $0.11 earnings per share. Enzymotec’s revenue was down 12.7% compared to the same quarter last year. On average, equities research analysts forecast that Enzymotec will post $0.27 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Algert Global LLC boosted its position in Enzymotec by 32.9% in the third quarter. Algert Global LLC now owns 50,566 shares of the company’s stock valued at $354,000 after buying an additional 12,520 shares during the period. Public Employees Retirement System of Ohio boosted its position in Enzymotec by 48.6% in the second quarter. Public Employees Retirement System of Ohio now owns 35,187 shares of the company’s stock valued at $294,000 after buying an additional 11,501 shares during the period. Menta Capital LLC boosted its position in Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock valued at $405,000 after buying an additional 5,362 shares during the period. Janus Capital Management LLC boosted its position in Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the period. Finally, Van ECK Associates Corp boosted its position in Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock valued at $106,000 after buying an additional 706 shares during the period. 36.20% of the stock is currently owned by institutional investors.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.